Tuning hERG Out: Antitarget QSAR Models for Drug Development

ISSN: 1873-5294 (Online)
ISSN: 1568-0266 (Print)


Volume 14, 24 Issues, 2014


Download PDF Flyer




Current Topics in Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 9th of 59 in Chemistry, Medicinal



Editor-in-Chief:
Allen B. Reitz
Fox Chase Chemical Diversity Center, Inc
Doylestown, PA
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.702
5 - Year: 3.885

Tuning hERG Out: Antitarget QSAR Models for Drug Development

Author(s): Rodolpho C. Braga, Vinicius M. Alves, Meryck F.B. Silva, Eugene Muratov, Denis Fourches, Alexander Tropsha and Carolina H. Andrade

Affiliation: LabMol, Faculdade de Farmacia, Universidade Federal de Goias, Rua 240, Qd. 87, Setor Leste Universitario, Goiania, Goias 74605-170, Brazil.

Abstract

Several non-cardiovascular drugs have been withdrawn from the market due to their inhibition of hERG K+ channels that can potentially lead to severe heart arrhythmia and death. As hERG safety testing is a mandatory FDArequired procedure, there is a considerable interest for developing predictive computational tools to identify and filter out potential hERG blockers early in the drug discovery process. In this study, we aimed to generate predictive and wellcharacterized quantitative structure–activity relationship (QSAR) models for hERG blockage using the largest publicly available dataset of 11,958 compounds from the ChEMBL database. The models have been developed and validated according to OECD guidelines using four types of descriptors and four different machine-learning techniques. The classification accuracies discriminating blockers from non-blockers were as high as 0.83-0.93 on external set. Model interpretation revealed several SAR rules, which can guide structural optimization of some hERG blockers into non-blockers. We have also applied the generated models for screening the World Drug Index (WDI) database and identify putative hERG blockers and non-blockers among currently marketed drugs. The developed models can reliably identify blockers and non-blockers, which could be useful for the scientific community. A freely accessible web server has been developed allowing users to identify putative hERG blockers and non-blockers in chemical libraries of their interest (http://labmol.farmacia.ufg.br/predherg).




Keywords: Antitarget, drug development, hERG, QSAR modeling, virtual screening.

Purchase Online Rights and Permissions

Article Details

Volume: 14
Issue Number: 11
First Page: 1399
Last Page: 1415
Page Count: 17
DOI: 10.2174/1568026614666140506124442
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science